-
Neuron Liu Kai's team found that activating type II interferon and cGAS-STING signaling pathways in the nervous system can promote axon regeneration
Time of Update: 2023-01-06
On November 11, 2022, Liu Kai's research group of the Hong Kong University of Science and Technology published a long article "Driving Axon Regeneration by Orchestrating Neuronal and Non-neuronal Innate Immune Responses via the" in Neuron IFNγ-cGAS-STING Axis, found that by knocking out PTPN2 and adding type II interferon stimulated genes (ISGs) in neurons including the cGAS-STING pathway, it was possible to activate interferon stimulated genes (ISGs).
-
Neuron Liu Kai's team found that activating type II interferon and cGAS-STING signaling pathways in the nervous system can promote axon regeneration
Time of Update: 2023-01-06
On November 11, 2022, Liu Kai's research group of the Hong Kong University of Science and Technology published a long article "Driving Axon Regeneration by Orchestrating Neuronal and Non-neuronal Innate Immune Responses via the" in Neuron IFNγ-cGAS-STING Axis, found that by knocking out PTPN2 and adding type II interferon stimulated genes (ISGs) in neurons including the cGAS-STING pathway, it was possible to activate interferon stimulated genes (ISGs).
-
Effects of FSHW sea cucumber flower hydrolysate on hypoglycemic and lipidemic effects in rats with type II diabetes
Time of Update: 2022-11-26
However, metformin and SCGH treatment significantly increased the protein expression levels of p-Akt and p-GSK-3β in rats with T2DM diabetes and decreased the protein expression of p-IRS1 in a dose-dependent manner 。 Studies have shown that amino acids such as Pro, Phe, Leu/Ile and Ala can alleviate glucose uptake and insulin resistance by activating the IRTK/PI3K/GLUT4 signaling pathway, and the abundance of Pro (7.
-
New Harvard University study of nearly 200,000 people: People who are not overweight lose weight increase their risk of type II diabetes
Time of Update: 2022-10-13
In addition, there is currently insufficient research on long-term weight changes and the risk of developing type II diabetes (T2D) after trying various weight loss strategies (WLS).
-
ARD: The Huayinghui team revealed that type II collagen promotes gouty arthritis by regulating sodium urate crystals and inflammatory cell recruitment
Time of Update: 2022-10-12
On September 15th, the Hua Yinghui team of the Department of Sports Medicine of Huashan Hospital affiliated to Fudan University carried out research based on clinical surgical experience, combined wi
-
BIOIBERICA and BY-HEALTH have introduced natural (non-denatured) type II collagen to China
Time of Update: 2022-10-04
Bioiberica, a global life sciences company focused on extracting bioactives with health value for the nutraceutical and pharmaceutical industries, has now partnered with By-Health, a leading Chinese v
-
"Night owls" are at greater risk of developing type II diabetes and heart disease
Time of Update: 2022-09-30
The researchers said that the difference in fat metabolism between "early birds" and "night owls" suggests that the body's circadian rhythm may affect the way insulin is used, which has a significant impact on human health.
-
J Autoimmunity: A panel of type II interferon-regulated genes is associated with disease activity in patients with systemic lupus erythematosus
Time of Update: 2022-08-19
Objective: Upregulation of interferon-regulated genes (IRGs) in peripheral blood, expressed as an interferon (IFN) signature, has been used as an indirect measure of IFN pathway activation in patients with systemic lupus erythematosus (SLE) .
-
ARD: A phase II randomized trial of the type I interferon inhibitor anivolumab in patients with active lupus nephritis
Time of Update: 2022-04-16
Conclusions: Although the primary endpoint was not met, in patients with active lupus nephritis, anifrugumab IR improved endpoint values including complete renal response at 52 weeks compared with placebo .
-
Ren Wenkai/Professor Peng Yuanyi's teamwork revealed that melatonin targets type II citrate synthase to inhibit Gram-negative bacteria
Time of Update: 2022-01-26
Recently, Professor Ren Wenkai's research group from South China Agricultural University, Professor Peng Yuanyi's research group from Southwest University and Professor Liu Yuan's research group from Yangzhou University School of Veterinary Medicine jointly published a research titled "Melatonin inhibits Gram-negative pathogens by targeting citrate synthase" in Science China Life Sciences The paper reveals the antibacterial target and mechanism of melatonin-specific inhibition of Gram-negative bacteria .
-
Antisense RNA fine-tunes gene expression of the type II MazEF toxin-antitoxin system
Time of Update: 2022-01-24
Georg and Hess recently reviewed specific low-conservation asRNAs as important regulators of gene expression (6) Many asRNA-dependent gene regulatory mechanisms require the formation of double-stranded RNA duplexes from the base pairing of sense RNAs (sRNAs) and asRNAs .
-
Fosun Pharma’s MEK1/2 inhibitor initiates phase II clinical treatment for type I neurofibromas
Time of Update: 2022-01-13
Article source: Medical Rubik's Cube InfoRecently, Fosun Pharma issued an announcement stating that it has initiated a phase II clinical study of FCN-159 tablets for the treatment of type I neurofibromas .
-
Gale announced that the Phase II clinical trial application of ASC22 (envolimab) for immune
Time of Update: 2021-12-08
(Hong Kong Stock Exchange code: 1672) today announced that its ASC22 (Envolimab) Phase II clinical trial application has been approved by China Approved by the National Medical Products Administration (NMPA) as a new indication for immune reconstitution/functional cure for people infected with human immunodeficiency virus type 1 (HIV-1) .
-
JAMA Intern Med: Impact of SGLT-2 Inhibitors vs. Sulfonylureas on the Risk of Death in Patients with Type II Diabetes
Time of Update: 2021-07-31
Studies believe that compared with sulfonylureas, the use of metformin-SGLT-2 inhibitor combination therapy can reduce the risk of all-cause death in patients with type II diabetes .
Compared with sulfonylureas, combined treatment with metformin-SGLT-2 inhibitors can reduce the risk of all-cause death in patients with type II diabetes.
-
Mucopolysaccharidosis type II drug Hiresi® is put into commercial application
Time of Update: 2021-06-17
to solve this problem, we recommend that the parties should promote the registration of mucopolysaccharide storage disease patients, which will help experts understand the status of epidemiology mucopolysaccharidosis our country, clinical treatment and health care, Help policy decision-making departments to formulate intervention strategies for high-risk groups, improve the diagnosis and treatment service system, improve the level of patient medical protection, and provide scientific basis for improving the availability of drugs .